P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

In a recent study posted to the bioRxiv* pre-print server, a team of researchers investigated P323L in RNA polymerase (NSP12) and D614G in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to understand the selection pressure at these two mutation sites.

Study: Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype. Image Credit: Andrii Vodolazhskyi/ShutterstockStudy: Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype. Image Credit: Andrii Vodolazhskyi/Shutterstock

NSP12, an RNA-dependent RNA polymerase complex, is composed of both viral and host cell proteins. The mechanism behind the selection pressure acting on the P323L mutation in humans and non-human primate animal models is unknown. The authors speculated that the P323L mutation in the NSP12 polymerase complex alters interactions with the host cell proteome, thus facilitating SARS-CoV-2 replication. Therefore, they cultured viruses in cell lines from the original host species speculating this might drive the selection, providing a mechanism to identify candidates for the original zoonotic event(s).

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The SARS-CoV-2 with D614G S mutation was first identified in February 2020, and by May 2020, ~80% of sequenced viruses contained this mutation. The SARS-CoV-2 Pango lineage B.1 and sub-lineages containing the D614G mutation also had potentially linked mutations, including C14407U in NSP12 that conferred a P323L mutation. However, A.19 and A.2.4 lineages had the D614G mutation but not the P323L mutation. Therefore, it is not entirely clear whether the P323L mutation in NSP12 confers a fitness advantage and is subject to selection pressure.

The study

In the present study, samples from coronavirus disease 2019 (COVID-19) patients were sequenced to analyze both the dominant viral genome sequence and minor variant genomes before and during the occurrences of D614G/P323L mutations in the UK to understand the dynamics of the within-host selection pressure for the P323L variant.

The researchers analyzed the SARS-CoV-2 population in humans when the two mutations became part of the dominant viral genome sequence. In addition, a lineage B SARS-CoV-2 with 323L and 614G in the minor variant population was studied in two non-human primates - cynomolgus (Macaca fascicularis) and rhesus (Macaca mulatta) macaques to review the mild COVID-19 observed in most humans.

Longitudinal sampling indicated that while the 323L mutation became part of the dominant viral genome sequence, 614G could not. Reverse genetic analysis of the P323L variant with a 614G mutation revealed that the P323L variant grew with a larger plaque phenotype providing a selective advantage to the D614G mutation in the S protein. Overall, this indicated that an emerging dominant sequence (and a new variant) could be predicted by an analysis of minor variant genomes.

Results

The analysis based on the study model suggested rapid selection of P323L in NSP12 and D614G in the spike protein within humans. Infection with a SARS-CoV-2 variant having a mutation in the minor variant genome under the selection pressure would have seen an increased proportion of this genome as the infection progresses until the minor variant genome became the dominant viral genome. However, this would not have happened if transmission occurred early during the infection. Under strong selection pressure, the viral population being transmitted would have mutated as part of the dominant viral genome which would have persisted during further infections. In addition, due to the founder effect, there might have been the sudden emergence of a mutation in the dominant genome sequence.

In the primate model, the SARS-CoV-2 variant used for infection was an isolate close to the original Wuhan strain which had the P323 mutation in NSP12 and the D614 mutation in the S protein of the dominant consensus sequence. At the minor variant genome level, the frequency of 323L in NSP12 was 0.03%, and that of 614G was 0.02%. The sequence analysis also indicated that some animals showed a dominant viral genome sequence containing 323L in NSP12, but not necessarily 614G in the spike protein.

Recombinant viruses that differed at codon 323 in NSP12 with the D614G mutation in the S grew with a smaller plaque morphology than a version with only 323L mutation in NSP12. Other determinants of plaque size are in vitro growth rate, evasion of antiviral responses, and cell to cell fusion.

Conclusions

The study findings suggest that, in some cases, tracking the distribution and frequency of SARS-CoV-2 minor variant genomes at a population level would help in predicting the emergence of a new dominant viral genome sequence. When combined with intensive computations requiring higher quality samples and sequencing data, researchers may also be able to predict a newly emerging SARS-CoV-2 variant quickly. It may also aid in the rapid evaluation of medical countermeasures and non-pharmaceutical interventions against these variants globally.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, May 10). P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20211230/P323L-mutations-in-SARS-CoV-2-are-highly-predictive-of-emergence-of-new-variants.aspx.

  • MLA

    Mathur, Neha. "P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20211230/P323L-mutations-in-SARS-CoV-2-are-highly-predictive-of-emergence-of-new-variants.aspx>.

  • Chicago

    Mathur, Neha. "P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants". News-Medical. https://www.news-medical.net/news/20211230/P323L-mutations-in-SARS-CoV-2-are-highly-predictive-of-emergence-of-new-variants.aspx. (accessed November 24, 2024).

  • Harvard

    Mathur, Neha. 2023. P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20211230/P323L-mutations-in-SARS-CoV-2-are-highly-predictive-of-emergence-of-new-variants.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients